{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms&page=39", "query": { "condition": "Neoplasms", "page": 39 }, "page_size": 10 }, "pagination": { "page": 39, "page_size": 10, "total_count": 50362, "total_pages": 5037, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms&page=40&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms&page=38&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T14:09:01.823Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003058", "title": "Troglitazone in Treating Patients With Liposarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "troglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 85, "start_date": "1997-06", "completion_date": "2000-01", "has_results": false, "last_update_posted_date": "2017-02-13", "last_synced_at": "2026-10-30T14:09:01.823Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003058" }, { "nct_id": "NCT00129558", "title": "A Study to Evaluate PT-523 in Patients With Refractory Leukemia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "PT-523 for Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2005-07", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-10-30T14:09:01.823Z", "location_count": 6, "location_summary": "Los Angeles, California • Chicago, Illinois • Durham, North Carolina + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00129558" }, { "nct_id": "NCT00576758", "title": "GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "obinutuzumab (RO5072759)", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2008-01", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-08-19", "last_synced_at": "2026-10-30T14:09:01.823Z", "location_count": 13, "location_summary": "Los Angeles, California • Denver, Colorado • Gainesville, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00576758" }, { "nct_id": "NCT03207347", "title": "A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mesothelioma", "Uveal Melanoma", "Renal Cell Carcinoma", "Cholangiocarcinoma" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 37, "start_date": "2018-08-13", "completion_date": "2022-08-30", "has_results": true, "last_update_posted_date": "2023-09-15", "last_synced_at": "2026-10-30T14:09:01.823Z", "location_count": 3, "location_summary": "Gainesville, Florida • Miami, Florida • Orlando, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03207347" }, { "nct_id": "NCT07493447", "title": "Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Meningioma", "Glioblastoma", "Acoustic Neuroma", "Brain Cancer", "Pituitary Adenoma" ], "interventions": [ { "name": "Panitumumab-IRDye800", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eben Rosenthal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-07-07", "completion_date": "2031-06", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-30T14:09:01.823Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07493447" }, { "nct_id": "NCT04214249", "title": "BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Acute Myeloid Leukemia Post Cytotoxic Therapy", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "Idarubicin Hydrochloride", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Punch Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 49, "start_date": "2021-02-17", "completion_date": "2027-01-30", "has_results": true, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-30T14:09:01.823Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Orange, California • New Haven, Connecticut + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04214249" }, { "nct_id": "NCT02244749", "title": "Role of Metabolic Enzymes in Non-Melanoma Skin Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Skin Cancer" ], "interventions": [ { "name": "skin specimen", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2011-03", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2022-11-01", "last_synced_at": "2026-10-30T14:09:01.823Z", "location_count": 2, "location_summary": "Irvine, California", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02244749" }, { "nct_id": "NCT02467738", "title": "Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Recurrent Head and Neck Carcinoma" ], "interventions": [ { "name": "Brachytherapy", "type": "RADIATION" }, { "name": "Cesium-131", "type": "DRUG" }, { "name": "Conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 30, "start_date": "2015-03-17", "completion_date": "2020-05-28", "has_results": false, "last_update_posted_date": "2025-09-19", "last_synced_at": "2026-10-30T14:09:01.823Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02467738" }, { "nct_id": "NCT05172258", "title": "Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hypopharyngeal Squamous Cell Carcinoma", "Metastatic Laryngeal Squamous Cell Carcinoma", "Metastatic Oral Cavity Squamous Cell Carcinoma", "Metastatic Oropharyngeal Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2022-07-26", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-30T14:09:01.823Z", "location_count": 20, "location_summary": "Duarte, California • Irvine, California • Lancaster, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05172258" }, { "nct_id": "NCT06476548", "title": "Mindfulness-Based Ecological Momentary Intervention For Smoking Cessation Among Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Any Cancer Type" ], "interventions": [ { "name": "EMI", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2024-06-12", "completion_date": "2024-08-26", "has_results": true, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-30T14:09:01.823Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06476548" } ] }